Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | G6PD | P11413 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | MPI | P34949 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11489856 | 0.90 | ESR1 (0.64) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL11650980 | 0.89 | ESR1 (0.63) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL11651828 | 0.89 | ESR1 (0.63) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL942015 | 0.87 | ESR1 (0.60) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL5529413 | 0.87 | ESR1 (0.60) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL5529409 | 0.87 | ESR1 (0.60) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL224399 | 0.84 | ESR1 (1.00) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL13123059 | 0.84 | ESR1 (1.00) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL224398 | 0.84 | ESR1 (1.00) | ESR1ESR2LMNAMAPTMAPK1 | |
| SCHEMBL6009933 | 0.84 | ESR1 (1.00) | ESR1ESR2LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0240717-A2 | Prevention of mammary carcinoma | Board of Regents of the University of Nebraska (US) | 1987-10-14 | — | — | EP | claimed |
| WO-2024259428-A2 | ESTROGENIC COMPOUNDS AND FORMULATIONS FOR GESTATION-RELATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| US-20060035875-A1 | Remedy for hormone-dependent cancer | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1568381-A1 | REMEDY FOR HORMONE-DEPENDENT CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-0240717-A2 | Prevention of mammary carcinoma | Board of Regents of the University of Nebraska (US) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035875-A1 | Remedy for hormone-dependent cancer | STS, CYP21A2, SHBG | ESR1 215/4885ESR2 235/4885LMNA 4511/4885 |
| US-20070021624-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | ESR1 462/4885ESR2 116/4885LMNA 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.